Drug Profile
Parsaclisib - Incyte Corporation
Alternative Names: IBI-376; INCB-050465; INCB-50465Latest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Developer Incyte Corporation; Innovent Biologics; Mayo Clinic; National Cancer Institute (USA)
- Class Antianaemics; Antihaemorrhagics; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Ketones; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Follicular lymphoma
- Phase III Myelofibrosis
- Phase II B-cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Phase I/II Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Solid tumours
- Preclinical Systemic lupus erythematosus
- Discontinued Autoimmune haemolytic anaemia; Sjogren's syndrome
Most Recent Events
- 09 Dec 2023 Efficacy and safety data from a phase I/II trial in Peripheral T-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 17 Oct 2023 Innovent Biologics withdraws a phase I trial in Follicular Lymphoma prior to enrolment (NCT05867030)
- 13 Oct 2023 Incyte Biosciences completes a phase II trial for Follicular lymphoma (Second-line therapy or greater) in Japan (PO) (NCT04434937)